Product news

Share this article:
Schering-Plough said the FDA has approved label revisions for Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin, USP) combination therapy for chronic hepatitis C, recommending weight-based dosing of Rebetol (800-1400 mg daily) based on patient body weight. The revised label also recommends a shorter, 24-week course of the combination therapy for patients with chronic hepatitis C virus genotype 2 or 3.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M inVISION